Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H23NO.ClH |
Molecular Weight | 317.853 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=LPRLDRXGWKXRMQ-UHFFFAOYSA-N
InChI=1S/C19H23NO.ClH/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17;/h2-11,18-19H,12-15H2,1H3;1H
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01146 | https://www.ncbi.nlm.nih.gov/pubmed/42012 | https://www.ncbi.nlm.nih.gov/pubmed/1912125
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01146 | https://www.ncbi.nlm.nih.gov/pubmed/42012 | https://www.ncbi.nlm.nih.gov/pubmed/1912125
Diphenylpyraline is an antihistamine that prevents but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline may exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1912125 |
4.1 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Belfene Approved UseUnknown |
|||
Primary | Belfene Approved UseUnknown |
|||
Primary | Belfene Approved UseUnknown |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4156058/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENYLPYRALINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
Title | Date | PubMed |
---|---|---|
Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis. | 1977 |
|
[Antimycobacterial antihistaminics]. | 1989 Aug |
|
Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. | 1991 Aug 15 |
|
Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. | 2001 Jan 1 |
|
Sensitive determination of pethidine in body fluids by surface ionization organic mass spectrometry. | 2001 Jul 5 |
|
Treatment of urethral sphincter mechanism incompetence in 11 bitches with a sustained-release formulation of phenylpropanolamine hydrochloride. | 2002 Sep 28 |
|
Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry. | 2006 |
|
Transition metal complexes of quinolino[3,2-b]benzodiazepine and quinolino[3,2-b]benzoxazepine: synthesis, characterization, and antimicrobial studies. | 2007 |
|
Antimycobacterial activity of diphenylpyraline derivatives. | 2008 Apr |
|
Development and validation of LC-MS/MS method for the determination of cyproheptadine in several pharmaceutical syrup formulations. | 2009 Dec 5 |
|
Development and validation of an LC-MS/MS confirmatory method for residue analysis of cyproheptadine in urine of food-producing animals. | 2009 Mar 25 |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1912125
Brain tissue was obtained at autopsy on 18 Japanese patients with chronic schizophrenia. The brain tissues were weighed, homogenized and centrifuged. The specific 3H-mepyramine binding to the brain tissues reached equilibrium values within 20 min after incubation at 25°C. Inhibition of the specific component of the 3H-mepyramine binding by Diphenylpyraline was then studied. The H1 antagonist diphenylpyraline (Ki=4.1nM) was potent competitors for the specific binding of 3H-mepyramine.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
61825
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
31508
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
SUB01778MIG
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
66063
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
DTXSID7047772
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
C65424
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
G9FU7F1E87
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
m4640
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
203155
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1492
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
DBSALT000807
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
205-049-3
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
100000087536
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
132-18-3
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY | |||
|
C009871
Created by
admin on Fri Dec 15 15:13:37 GMT 2023 , Edited by admin on Fri Dec 15 15:13:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD